Katja Sockel

Dresden, SN 01307, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 112 publications

Deep learning differentiates myeloproliferative neoplasms and predicts JAK2 and CALR mutations from bone marrow smears.

Deep learning differentiates myeloproliferative neoplasms and predicts JAK2 and CALR mutations from bone marrow smears.

Journal: Annals of hematology

Published: July 03, 2026

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Journal: Bone marrow transplantation

Published: April 26, 2026

Allogeneic Transplantation in the Rare Disease Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia: Age and Disease Burden Determine Outcome.

Allogeneic Transplantation in the Rare Disease Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia: Age and Disease Burden Determine Outcome.

Journal: Transplantation and cellular therapy

Published: April 10, 2026

Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine Outcome.

Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine Outcome.

Journal: Transplantation and cellular therapy

Published: April 10, 2026

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

Journal: American journal of hematology

Published: March 09, 2026

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD.

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD.

Journal: Bone marrow transplantation

Published: February 06, 2026

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: The Lancet. Haematology

Published: January 12, 2026

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Journal: Bone marrow transplantation

Published: November 30, 2025

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

Journal: Bone marrow transplantation

Published: September 05, 2025

Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML.

Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML.

Journal: HemaSphere

Published: September 05, 2025

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Journal: The Lancet. Haematology

Published: September 01, 2025

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss.

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss.

Journal: HemaSphere

Published: September 01, 2025

Showing 1-12 of 112

Last Updated: 09/26/2026